SRR934853
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 25.427069645203677
- age_years
- 33
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.508
- G2M_CHECKPOINT+0.483
- E2F_TARGETS+0.468
- WNT_BETA_CATENIN_SIGNALING+0.457
- NOTCH_SIGNALING+0.452
- MYC_TARGETS_V1+0.434
- MYC_TARGETS_V2+0.413
- DNA_REPAIR+0.410
- MITOTIC_SPINDLE+0.373
- UNFOLDED_PROTEIN_RESPONSE+0.293
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.412
- MYOGENESIS-0.386
- KRAS_SIGNALING_DN-0.376
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- COAGULATION-0.296
- ESTROGEN_RESPONSE_LATE-0.288
- ALLOGRAFT_REJECTION-0.271
- COMPLEMENT-0.271
- INFLAMMATORY_RESPONSE-0.268
- CHOLESTEROL_HOMEOSTASIS-0.267
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4A2E75AE-A92F-4497-9253-64AC42CFA745 | — | — | 0.940 |
| 2 | 848C73F3-ABD7-47FD-BF70-FF29FBDF6F61 | — | — | 0.935 |
| 3 | SRR934880 | — | — | 0.935 |
| 4 | SRR934847 | — | — | 0.925 |
| 5 | 4938761D-0762-4984-A399-BC036D6D2140 | — | — | 0.923 |
| 6 | 4FC69960-8EF2-49FE-A718-7004E99E00A8 | — | — | 0.920 |
| 7 | 0D1652B9-93F6-4D1A-BF06-B654663C92E3 | — | — | 0.915 |
| 8 | SRR934879 | — | — | 0.915 |
| 9 | 694B3BE3-104F-4D90-8733-4E99230EFAC6 | — | — | 0.910 |
| 10 | 4FD9ED95-21E7-440D-AAA9-86DDDF12B37A | — | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.508 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.483 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.468 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.457 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.452 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.434 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.413 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.410 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.373 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.293 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.237 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.101 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.088 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.027 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.027 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.006 | Inavolisib | — uncovered |